Biotech News

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Roivant (ROIV)Roivant2026-09-23 11:00 ESTClinical readout

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

ROIVRoivant2026-10-21 11:01 EST

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

ROIVRoivant2026-10-21 11:00 EST

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

ROIVRoivant2026-09-23 11:00 EST